China Biopharma to launch MNC's drugs

Hangzhou-based China Biopharma says that it has reached agreement with Beijing Keyuan Xinhai Pharmaceutical Company to launch newly-approved products made by leading international pharmaceutical companies. According to the agreement, China Biopharma will distribute pharmaceutical products made by multinational drugmakers, including human vaccines, in China using the partner's sales network and distribution logistics.

In the last few months, the company has made efforts to extend its market scope and establish new partnerships in addition to the original joint venture partner, Zhejiang Tianyuan Bio-pharmaceutical. Due to certain local tax regulations, the company's sales of the products of its original JV partner could not be fully recognized.

In order to effectively conduct its business operation and change from a passive marketing approach in China, the company has shifted its commercialization strategy to working more closely with new pharmaceutical products from leading global pharmaceutical companies in addition to local products.